FDA OKs Phase 1 Trial to Test Celyad’s Donor-derived CAR T-cell Therapy in Colorectal Cancer

FDA OKs Phase 1 Trial to Test Celyad’s Donor-derived CAR T-cell Therapy in Colorectal Cancer
1
(1)

Celyad will soon begin clinical development of its immunotherapy CYAD-101 (CAR-T NKG2D) and evaluate its potential as a treatment for patients with colorectal cancer that cannot be surgically removed.

The first-in-human Phase 1 trial, called Allo-SHRINK, comes after the approval of an investigational new drug application for CYAD-101 by the U.S. Food and Drug Administration.

Traditionally, CAR T-cell therapies consist of the collection of a patient’s own immune cells, which are modified in the lab to recognize cancer cells, expanded, and injected back into the patient.

But while autologous (patient-derived) CAR T-cell therapies have shown promise in multiple cancer types, researchers aren’t always able to collect enough cells from a patient to create the treatment.

This led Celyad to develop CYAD-101, which is an allogeneic CAR T-cell therapy, meaning immune cells are collected from healthy donors, rather than the patient.

CYAD-101 is based on features of CYAD-01, an investigational autologous CAR T-cell treatment also being developed by Celyad. Cells in CYAD-01 produce a chimeric receptor — called NKG2D — that recognizes multiple tumor proteins, a promising approach for nearly 80 percent of all cancers.

Because it is derived from genetically different individuals, cells in CYAD-101 also carry a molecule that prevents the patients’ immune system from recognizing them as foreign.

“We are pleased to have achieved this important milestone,” Christian Homsy, MD, CEO of Celyad, said in a press release. “Celyad is the first company clinically evaluating a non-gene edited CAR-T candidate, which, we believe, offers significant advantages over gene edited approaches.”

Celyad’s autologous approach, CYAD-01, is being tested in three Phase 1 trials for different cancers.

SHRINK (NCT03310008) is a study testing increasing doses of CYAD-01, given along with chemotherapy, in colorectal cancer patients whose liver metastasis may be removed by surgery.

The LINK study (NCT03370198) is assessing asceding doses of CYAD-01 in colorectal cancer patients with liver metastases that cannot be removed by surgery. The treatment is given alone and injected directly into the liver artery.

A third trial (NCT03018405) is evaluating CYAD-01 in seven types of refractory cancers, including five solid tumors — colorectal, ovarian, bladder, triple-negative breast, and pancreatic cancers — and two blood cancers — acute myeloid leukemia and multiple myeloma.

Preliminary data from SHRINK and LINK showed no treatment-related toxicities in the first patient treated in each trial.

“Our non-gene edited program consists of a family of technologies aimed at reducing or eliminating T cell receptor (TCR) signaling without requiring genetic manipulation,” Homsy said. “CYAD-101 is part of a robust clinical development plan, establishing the foundations of next generation CAR-T products.”

How useful was this post?

Click on a star to rate it!

Average rating 1 / 5. Vote count: 1

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?